Breathe Well Live Well
fox4kc.com |
More insurers covering first non-drug treatment for severe asthma
fox4kc.com OVERLAND PARK, Kan. — The first non-drug treatment for severe asthma has been available for five years, but it's only recently that patients have started having success in getting insurers to cover the procedure that costs more than $20,000. Michelle … |
View full post on asthma – Google News
FierceHealthPayer |
Insurers reluctant to cover pricey bronchial thermoplasty asthma treatment
FierceHealthPayer BCBS changed its policy based on bronchial thermoplasty studies and noted that only a small subset of individuals with severe asthma meet the criteria, which includes demonstrating that previous asthma drug treatments didn't work, HCSC spokeswoman … |
View full post on asthma – Google News
|
Insurers balk at asthma treatment that doesn't involve drugs
Insurance News Net "Most asthma is easy to control with great drugs and inhalers, but there is a group of people that despite all that, their asthma is still a huge problem for them," Hogarth said. "So what do you do for that group? And that's where thermoplasty comes in . |
View full post on asthma – Google News
Chicago Tribune |
Insurers balk at asthma treatment that doesn't involve drugs
Chicago Tribune "Most asthma is easy to control with great drugs and inhalers, but there is a group of people that despite all that, their asthma is still a huge problem for them," Hogarth said. "So what do you do for that group? And that's where thermoplasty comes in . |
View full post on asthma – Google News
|
Aerocrine's novel asthma test in search of doctors, insurers [The News …
Insurance News Net (press release) With $22 million in cash, Aerocrine is positioned to finance operations through 2012, according to one analyst report, putting a premium on increased sales for its relatively unknown asthma test. The 15-year-old company, based on a scientific discovery … |
View full post on asthma – Google News
|
Aerocrine's novel asthma test in search of doctors, insurers
News & Observer With $22 million in cash, Aerocrine is positioned to finance operations through 2012, according to one analyst report, putting a premium on increased sales for its relatively unknown asthma test. The 15-year-old company, based on a scientific discovery … |
View full post on asthma – Google News